

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shukuya T, Takahashi T, Harada H, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N	Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older	Jpn J Clin Oncol	43(2)	176-183	2013
Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N	The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who received concurrent chemoradio therapy	Am J Clin Oncol	[Epub ahead of print]		2012
Watanabe R, Ito I, Kenmotsu H, Endo M, Yamamoto N, Ohde Y, Kondo H, Nakajima T, Kameya T	Large Cell Neuroendocrine Carcinoma of the Lung: Is it Possible to Diagnose from Biopsy Specimens?	Jp J Cli Oncol	43(3)	294-304	2013

<p>Serizawa M,  <u>Takahashi T</u>,  <u>Yamamoto N</u>,  Koh Y</p>	<p>Combined treatment with erlotinib and a transforming growth factor-b type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.</p>	<p>J Thorac Oncol</p>	<p>8(3)</p>	<p>259-269</p>	<p>2013</p>
<p>Kiyota H,  Okamoto I,  Takeda M, Daga H,  Naito T,  Miyazaki M,  Okada H,  Hayashi H,  Tanaka K,  Terashima M,  Azuma K,  Murakami H,  <u>Takeda K</u>,  <u>Yamamoto N</u>,  Nakagawa K</p>	<p>Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.</p>	<p>Cancer Chemother Pharmacol</p>	<p>71(4)</p>	<p>859-865</p>	<p>2013</p>
<p>Wakuda K,  Kenmotsu H,  Naito T,  Akamatsu H,  Ono A, Shukuya T,  Nakamura Y,  Tsuya A,  Murakami H,  <u>Takahashi T</u>,  Endo M,  Nakajima T,  <u>Yamamoto N</u></p>	<p>Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.</p>	<p>Am J Clin Oncol</p>	<p>Epub ahead of print</p>		<p>2013</p>

<u>Harada H,</u> <u>Nishio M,</u> Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, <u>Takahashi T,</u> Horiike A, Nishimura T, <u>Yamamoto N</u>	Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer	Clin Lung Cancer	14(4)	440-445	2013
Tokito T, Shukuya T, Akamatsu H, Taira T, Ono A, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, <u>Yamamoto N</u>	Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.	Cancer Chemother Pharmacol	71(6)	1493-1498	2013
Akamatsu H, <u>Inoue A,</u> Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, <u>Yamamoto N</u>	Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two phase III trials (NEJ 002 and WJTOG3405).	Jp J Clin Oncol	43(6)	664-668	
Imai H, Shukuya T, <u>Takahashi T,</u> Fujiwara S, Mori K, Ono A, Akamatsu H,	Comparison of the time to response between radiotherapy and epidermal growth factor receptor - tyrosine kinase inhibitors for advanced	Anticancer Res	33	3279-3284	

Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, <u>Harada H</u> , Endo M, Nakajima T, <u>Yamamoto N</u>	non-small cell lung cancer with EGFR mutation.				
Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Tanaka T, Yoshikawa T, Naito T, <u>Takahashi T</u> , Murakami H, Nakamura Y, Tsuya A, Shukuya T, Ono A, Akamatsu H, Watanabe R, Ono S, Kanbara H, Yamaguchi K, Matsunaga T, <u>Yamamoto N</u>	Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.	PLoS One	8(6)	e67466	
Nakamura M, Murakami H, Naito T, Kenmotsu H, Taira T, Akamatsu H, Ono A, Imai H, <u>Takahashi T</u> , Endo M, Nakajima T, Ode Y, <u>Yamamoto N</u>	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery.	Mol Clin Oncol	1	949-952	

Tsuya A, Kurata T, Tamiya A, Okamoto I, Ueda S, Sakai D, Sugimoto N, Matsumoto K, Goto I, Yamamoto N, Fukuoka M, Nakagawa K	A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.	Invest New Drugs	31	1568 1572	-	
Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Nakajima T, Endo M, Yamamoto N	Prognostic impact of serum CYFRA 21 - 1 in patients with advanced lung adenocarcinoma: a retrospective study.	BMC Cancer	13	354		
Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K	Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.	Cancer Sci	104(9)	1198-1204	2013	

Kawano Y, Ohyanagi F, Yanagitani N, Kudo K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T, Nakatomi K, Hagiwara S, Ninomiya H, Motoi N, Ishikawa Y, Horai T, <u>Nishio M</u>	Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.	Anticancer Res	33(8)	3327-3333	2013
Yoshida T, Yoh K, <u>Goto K</u> , Niho S, Umemura S, Ohmatsu H, Ohe Y	Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.	Anticancer Res	33(3)	1175-1179	2013
Yoshida T, Ishii G, <u>Goto K</u> , Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y, Ochiai A	Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.	J Cancer Res Clin Oncol	139(10)	1691-1700	2013
Takahashi A, Ishii G, Kinoshita T, Yoshida T, Umemura S, Hishida T, Yoh K, Niho S, <u>Goto</u>	Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine	J Cancer Res Clin Oncol	139(11)	1869-1878	2013

<u>K</u> , Ohmatsu H, Ohe Y, Nagai K, Ochiai A	carcinomas of the lung.				
Suzuki M, Makinoshima H, Matsumoto S, Suzuki A, Mimaki S, Matsushima K, Yoh K, <u>Goto K</u> , Suzuki Y, Ishii G, Ochiai A, Tsuta K, Shibata T, Kohno T, Esumi H, Tsuchihara K	Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.	Cancer Sci	104(7)	896-903	2013
Suzuki A, Mimaki S, Yamane Y, Kawase A, Matsushima K, Suzuki M, <u>Goto K</u> , Sugano S, Esumi H, Suzuki Y, Tsuchihara K	Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts.	PLoS One	8(9)	e73484	2013
Shiozawa T, Ishii G, <u>Goto K</u> , Nagai K, Mimaki S, Ono S, Niho S, Fujii S, Ohe Y, Tsuchihara K, Ochiai A	Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.	Pathol Int	63(2)	77-84	2013

Horinouchi H, Sekine I, Sumi M, Noda K, <u>Goto</u> <u>K</u> , Mori K, Tamura T	Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.	Cancer Sci	104(1)	93-97	2013
<u>Kaneda</u> H, Yoshida T, Okamoto I	Molecularly targeted approaches herald a new era of non - small cell lung cancer treatment.	Cancer Manage Res	7(5)	91-101	2013
Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, <u>Kaneda</u> H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M	Phase II study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naïve patients with advanced nonsquamous non-small cell lung cancer.	Cancer	119(12)	2275-2281	2013
Okamoto K, Okamoto I, Miyazaki M, Tanaka K, <u>Kaneda</u> H, Nakagawa K	Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.	Invest New Drugs	31(5)	1364-1366	2013
Kawahara M, Atagi S, Komuta K, Yoshioka H,	Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small	Anticancer Res	33(10)	4631-4637	2013

Kawasaki M, Fujita Y, Yonei T, Ogushi F, Kubota K, Nogami N, Tsuchiya M, Shibata K, Tomizawa Y, Minato K, Fukuoka K, Asami K, <u>Yamanaka T</u>	cell lung cancer.				
Yamaguchi M , Toyokawa G, Ohba T, Sasaki T ,Kometani T, Hamatake M, Hirai F, Taguchi K, <u>Yamanaka T</u> , <u>Seto T</u> , Takenoyama M, Sugio K, Ichinose Y	Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer.	Ann Thorac Surg	96	1783-1789	2013
Tsutani Y, Miyata Y, <u>Yamanaka T</u> , Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M	Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: Prognostic comparison using high-resolution computed tomography findings.	J Thorac Cardiovasc Surg	146(1)	17-23	2013
Oki M, <u>Saka H</u>	New dedicated bifurcated silicone stent placement for stenosis	Chest	144(2)	450-455	2013

	around the primary right carina.				
Oki M, <u>Saka H</u> , Kitagawa C, Kogure Y, Murata N, Adachi T, Ando M	Rapid on-site cytologic evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing lung cancer: a randomized study.	Respiration	85(6)	486-492	2013
Kawaguchi T, Ando M, Ito N, Isa S, Tamiya A, Shimizu S, <u>Saka H</u> , Kubo A, Koh Y, Matsumura A	Rationale and design of the Japan molecular epidemiology for lung cancer study.	Lung Cancer	Lung Cancer	596-600	2013
Oki M, <u>Saka H</u> , Kitagawa C, Kogure Y, Murata N, Adachi T, Ando M	Randomized study of endobronchial ultrasound-guided transbronchial biopsy: thin bronchoscopic method versus guide sheath method.	J Thorac Oncol	7(3)	535-541	2013
<u>Takayama K</u> , Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y	Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.	Cancer Chemother Pharmacol	72	1353-1359	2013

Wang S, <u>Takayama K</u> , Tanaka K, Takeshita M, Nakagaki N,Ijichi K, Li H, Nakanishi Y.	Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by $\alpha 1$ nicotinic acetylcholine receptor-mediated activation in PC9 cells.	J Thorac Oncol	8	719-725	2013
Yamada K, <u>Takayama K</u> , Kawakami S, Saruwatari K, Morinaga R, Harada T, Aragane N, Nagata S, Kishimoto J, Nakanishi Y, Ichinose Y.	Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK 0803).	Jpn J Clin Oncol	43	629-635	2013
Kang JH, Mori T, Kitazaki H, Niidome T, <u>Takayama K</u> , Nakanishi Y, Katayama Y.	Kinase activity of protein kinase ca in serum as a diagnostic biomarker of human lung cancer.	Anticancer Res	33	485-488	2013
Furuyama K, Harada T, Iwama E, Shiraishi Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, <u>Takayama K</u> , <u>Giaccone G</u> , Nakanishi Y.	Sensitivity and kinase activity of epidermal growth factor-receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.	Cancer Sci	104	584-589	2013

Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, <u>Nokihara</u> H, Yamamoto N, Sekine I, Tamura T	Short Hydration in chemotherapy containing cisplatin ( $\geq 75$ mg/m <sup>2</sup> ) for patients with lung cancer: a prospective study.	Jpn J Clin Oncol	43(11)	1105-1109	2013
Kuroda Y, Sekine I, Sumi M, Sekii S, Takahashi K, Inaba K, Horinouchi H, <u>Nokihara</u> H, Yamamoto N, Kubota K, Murakami N, Morota M, Mayahara H, Ito Y, Tamura T, Nemoto K, Itami J	Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer.	Technol Cancer Res Treat	12(4)	333-339	2013
Horinouchi H, Sekine I, Sumi M, Ito Y, <u>Nokihara</u> H, Yamamoto N, Ohe Y, Tamura T.	Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor.	Cancer Sci	103(4)	756-759	2013

<p><u>Inoue A</u>, Kobayashi K, Maemondo M, Sugawara S, <u>Oizumi S</u>, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, and Nukiwa T, for the North-East Japan Study Group</p>	<p>updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).</p>	<p>Ann Oncol</p>	<p>24(1)</p>	<p>54-59</p>	<p>2013</p>
<p>Harada T, <u>Oizumi S</u>, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, <u>Inoue A</u>, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M</p>	<p>Hokkaido Lung Cancer Clinical Study Group. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901</p>	<p>Oncologist</p>	<p>18(4)</p>	<p>439-445</p>	<p>2013</p>

Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chuda T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, <u>Inoue A</u> , Lee SM, GebSKI V, Yang JC	Impact of epidermal growth factor receptor inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.	J Natl Cancer Inst	105	595-605	2013
Sugawara S, Maemondo M, Tachihara M, <u>Inoue A</u> , Ishimoto O, Sakakibara T, Usui K, Watanabe H, Matsubara N, Watanabe K, Kanazawa K, Ishida T, Saijo Y, Nukiwa T	North Japan Lung Cancer Study Group: Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCC 0601.	Lung Cancer	81	91-96	2013